Abstract 64P
Background
The burden of metastatic breast cancer (mBC) is high in many low-middle income countries. Given the wider social and economic implications associated with advanced cancer, understanding the unmet needs of patients with mBC is crucial towards the design and provision of tailored supportive care. We aimed to determine the unmet needs of women newly diagnosed with mBC in a middle-income Asian setting with limited cancer survivorship services.
Methods
Women who were diagnosed with mBC in the 12 months preceding the study were recruited from a Ministry of Health hospital, an academic hospital, and two private hospitals in Malaysia, an upper-middle income Asian country. Unmet needs were assessed using the Needs Assessment Tool for Breast Cancer (NeAT-BC), a 48-item dual language questionnaire that we had previously developed and validated in the local setting.
Results
In this interim analysis with 96 participants, 74% of women indicated having at least one unmet need. The highest unmet needs were reported for the hospital appointments domain (79.2%) as well as the information and services domain (80.2%). Besides the need for shorter waiting times in the hospital (88.5%), many women also described having unmet needs regarding information on daily aspects of living including on diet (79.2%) and self-care (78.1%). Finance-wise, 62.5% reported needing help to pay for their cancer therapies, while 59.4% expressed an unmet need for affordable transportation options to the hospital. In this setting with strong sociocultural beliefs on traditional and complementary therapies (TCM), 53.1% of women with mBC reported an unmet need for open discussions with their healthcare providers on the use of TCM. No significant differences in the overall level of unmet needs were observed by age, ethnicity, hospital type, education level, and ownership of health insurance (p>0.05).
Conclusions
A high burden of unmet needs were observed among women with mBC in this middle-income Asian setting with limited supportive care services. In resource-limited settings, routine assessment of unmet needs as well as presence of dedicated personnel to navigate access to supportive services may play a key role in alleviating these needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University Malaya.
Funding
Novartis Corporation (M) Sdn Bhd.
Disclosure
N. Bhoo-Pathy: Financial Interests, Personal and Institutional, Research Funding: Novartis, Zuellig Pharma; Financial Interests, Personal, Other, Honorarium: Novartis, Pfizer, Roche; Non-Financial Interests, Personal and Institutional, Other, Research equipment: Roche Diagnostics. M. Thiagarajan: Non-Financial Interests, Personal and Institutional, Advisory Role: Jannsen, Astellas, MSD, Pfizer, Novartis; Financial Interests, Personal and Institutional, Research Funding: Novartis, MSD, Jannsen, Roche. N.F. Bt Abdul Satar: Financial Interests, Personal, Other, Honoraria: Roche, MSD Malaysia, Eisai, Ipsen Pharma; Financial Interests, Personal, Other, Honorarium: Pfizer, Zuellig Pharma; Financial Interests, Personal and Institutional, Research Funding, PI Clinical Trial: MSD Malaysia, Naluri Sdn Bhd, Viracta Therapeutics, KURA Oncology; Non-Financial Interests, Personal, Project Lead: Cancer ECHO UM. M. Md Yusof: Financial Interests, Institutional, Advisory Board, disease and treatment indications advisory board or expert committee meeting, as panellist or chair or speaker: AstraZeneca, Specialsed Therapeutics, Roche, MSD, Pfizer, Novartis, Eli Lily, Eisai; Financial Interests, Institutional, Invited Speaker, disease and treatment indications -speaker: Amgen; Financial Interests, Institutional, Invited Speaker, invited speaker for local conferences: Zuellig Pharma; Financial Interests, Institutional, Invited Speaker, speaker: Mundi Pharma, GSK; Financial Interests, Institutional, Other, speaker for doctors only platform webinar: Docquity; Financial Interests, Personal, Advisory Board, advisory board member for amivantamab in exon 20 insertion tve cancer: Johnson and Johnson; Financial Interests, Personal, Ownership Interest, surgery and oncology centre small partnership: Integrated Oncology Centre ( Kuala Lumpur) Sdn Bhd; Financial Interests, Personal and Institutional, Local PI, KEYNOTE 119, KEYNOTE 355, KEYNOTE B49, KEYNOTE4280A, KEYNOTE 076: MSD; Financial Interests, Personal and Institutional, Funding, local funding for multicentre data collection and reporting: Mundi Pharma; Financial Interests, Personal and Institutional, Local PI, Compleement1, EPIKB3, CANOPY-A: Novartis; Financial Interests, Personal and Institutional, Local PI, CAPITELLO, L-MOCA, ADAURA-A, SERENA-4: AstraZeneca; Financial Interests, Personal and Institutional, Local PI, GLOW study: Astellas; Financial Interests, Personal and Institutional, Local PI, ARc -10 study: ARCUS 10; Non-Financial Interests, Personal, Leadership Role, secretary: Malaysian Oncological Society; Non-Financial Interests, Personal, Advisory Role, clinician advisor: Breast Cancer women association ( NGO), KANWORK ( NGO); Non-Financial Interests, Personal, Advisory Role, government led group to evaluate the cost effectiveness of neoadjuvant anti HER2 therapy: Health Technology Assessment Trastuzumab in neoadjuvant treatment early breast cancer; Non-Financial Interests, Personal, Advisory Role, Clinical Practice Guideline for Breast Cancer 2020-2021: Ministry of Health Malaysia; Non-Financial Interests, Personal, Advisory Role, Specialty Education Subcommittee: Malaysian Medical Council Malaysia; Non-Financial Interests, Personal, Principal Investigator, PALOMA-3 trial: Johnson and Johnson. R. Kaur: Financial Interests, Personal, Other, Honoraria for consultancy and advisory role: Roche, Pfizer, Novartis, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract